Dicerna Licenses City of Hope RNAI IP and Pulls Down $13 million Series A
This article was originally published in Start Up
Executive Summary
Dicerna Pharmaceuticals hopes to elude the IP fortresses of Alnylam and Merck with a license to RNA interference IP out of City of Hope's Beckman Research Institute. If successful, this adjacent doorway into RNAi could create a new option for those pharma companies that have thus far stayed on the sidelines of the RNAi game.
You may also be interested in...
MiNA Pursuing The Other Side Of RNA Interference With Small Activating RNA Approach
London biotech seeks to up-regulate CEBP alpha gene in the liver to provide a therapeutic option for patients with both cirrhosis and hepatocellular carcinoma. MiNA’s first candidate is in Phase I and should move into a pair of Phase II trials in 2017.
Researchers To Tackle New Macular Degeneration Target Using Antisense
A research team has identified a way to treat the dry form of advanced age-related macular degeneration, for which no therapy exists to halt the associated vision loss. The team expects to start clinical testing of an antisense compound to address the problem, an accumulation of a type of RNA, by the end of the year.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007
We present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for October-December 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.